Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04618263 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers
A Phase 1 study, sponsored by Syndeio Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04618263: Clinical Trial Phase 1 study, sponsored by Syndeio Biosciences.
NCT04618263 is a Phase 1 study that was terminated before completion, run by Syndeio Biosciences. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04618263, a Phase 1 study, was terminated before completion, sponsored by Syndeio Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
To evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GATE-101 in normal human volunteers
Primary Outcome
Safety and Tolerabiity
Interventions
- DRUG GATE-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2020-10-26 |
| Est. Completion | 2021-08-13 |
| Phase | Phase 1 |
Why NCT04618263 stopped before completion
NCT04618263 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which GATE-101 is the first listed.
NCT04618263 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04618263 about?
NCT04618263 is a clinical study titled "Safety and Tolerability of Single and Multiple Ascending Doses of GATE-101 in Normal Human Volunteers". To evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of GATE-101 in normal human volunteers
What is the current status of trial NCT04618263?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2020-10-26. Estimated completion is 2021-08-13.
What interventions are being tested in trial NCT04618263?
The interventions under investigation include: GATE-101 (DRUG).
Who is sponsoring clinical trial NCT04618263?
This trial is sponsored by Syndeio Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04618263's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI